Literature DB >> 33245350

Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.

Oluwaseun Falade-Nwulia1, Mark S Sulkowski1.   

Abstract

The availability of safe, efficacious, oral direct-acting antivirals (DAAs) have ushered in a new era of hepatitis C treatment with potential to eliminate hepatitis C as a public health threat. To achieve population-level effectiveness of these oral DAAs, hepatitis C treatment by a wide range of providers in different settings will be essential to increase the number of persons treated. We provide a clinical review of hepatitis C treatment with a focus on practical tools for management of hepatitis C in majority of currently infected individuals who can be easily cured and optimization of treatment for those in whom treatment may not be as simple.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  hepatitis C; oral direct-acting antivirals; treatment

Mesh：

Substances：

Year:  2020        PMID： 33245350      PMCID： PMC8171802          DOI： 10.1093/infdis/jiaa534

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  107 in total

1.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Authors:  Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns
Journal:  Lancet Infect Dis       Date:  2016-02-18       Impact factor: 25.071

2.  Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

Authors:  Evguenia S Svarovskaia; Hadas Dvory-Sobol; Neil Parkin; Christy Hebner; Viktoria Gontcharova; Ross Martin; Wen Ouyang; Bin Han; Simin Xu; Karin Ku; Sophia Chiu; Edward Gane; Ira M Jacobson; David R Nelson; Eric Lawitz; David L Wyles; Neby Bekele; Diana Brainard; William T Symonds; John G McHutchison; Michael D Miller; Hongmei Mo
Journal:  Clin Infect Dis       Date:  2014-09-28       Impact factor: 9.079

3.  Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.

Authors:  Tarik Asselah; Kris V Kowdley; Neddie Zadeikis; Stanley Wang; Tarek Hassanein; Yves Horsmans; Massimo Colombo; Filipe Calinas; Humberto Aguilar; Victor de Ledinghen; Parvez S Mantry; Christophe Hezode; Rui Tato Marinho; Kosh Agarwal; Frederik Nevens; Magdy Elkhashab; Jens Kort; Ran Liu; Teresa I Ng; Preethi Krishnan; Chih-Wei Lin; Federico J Mensa
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-22       Impact factor: 11.382

4.  Boceprevir for untreated chronic HCV genotype 1 infection.

Authors:  Fred Poordad; Jonathan McCone; Bruce R Bacon; Savino Bruno; Michael P Manns; Mark S Sulkowski; Ira M Jacobson; K Rajender Reddy; Zachary D Goodman; Navdeep Boparai; Mark J DiNubile; Vilma Sniukiene; Clifford A Brass; Janice K Albrecht; Jean-Pierre Bronowicki
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

5.  All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population.

Authors:  Samer S El-Kamary; Ravi Jhaveri; Michelle D Shardell
Journal:  Clin Infect Dis       Date:  2011-06-10       Impact factor: 9.079

6.  Public Health Clinic-Based Hepatitis C Treatment.

Authors:  Amanda M Rosecrans; Aneesha Cheedalla; Sarah T Rives; Lisa A Scotti; Robert E Harris; Adena H Greenbaum; Risha R Irvin; Boatemaa A Ntiri-Reid; Holly T Brown; Karen E Alston; Jaeson A Smith; Kathleen R Page; Oluwaseun O Falade-Nwulia
Journal:  Am J Prev Med       Date:  2020-05-16       Impact factor: 5.043

7.  Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Authors:  David L Wyles; Peter J Ruane; Mark S Sulkowski; Douglas Dieterich; Anne Luetkemeyer; Timothy R Morgan; Kenneth E Sherman; Robin Dretler; Dawn Fishbein; Joseph C Gathe; Sarah Henn; Federico Hinestrosa; Charles Huynh; Cheryl McDonald; Anthony Mills; Edgar Turner Overton; Moti Ramgopal; Bruce Rashbaum; Graham Ray; Anthony Scarsella; Joseph Yozviak; Fiona McPhee; Zhaohui Liu; Eric Hughes; Philip D Yin; Stephanie Noviello; Peter Ackerman
Journal:  N Engl J Med       Date:  2015-07-21       Impact factor: 91.245

Review 8.  Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.

Authors:  Kris V Kowdley; Vinay Sundaram; Christie Y Jeon; Kamran Qureshi; Nyan L Latt; Amandeep Sahota; Stephen Lott; Michael P Curry; Naoky Tsai; Nathorn Chaiyakunapruk; Yoori Lee; Jorg Petersen; Peter Buggisch
Journal:  Hepatology       Date:  2017-02-25       Impact factor: 17.425

9.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

Review 10.  Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.

Authors:  Bryony Simmons; Jawaad Saleem; Katherine Heath; Graham S Cooke; Andrew Hill
Journal:  Clin Infect Dis       Date:  2015-05-17       Impact factor: 9.079
View more
  3 in total

1.  Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study).

Authors:  Daniel O'Keefe; J Gunn; Kathleen Ryan; Filip Djordjevic; Phoebe Kerr; Judy Gold; Imogen Elsum; Chloe Layton; Kico Chan; Paul Dietze; Peter Higgs; Joseph Doyle; Mark A Stoové; Margaret Hellard; A E Pedrana
Journal:  BMJ Open       Date:  2022-01-04       Impact factor: 2.692

2.  24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy.

Authors:  Laura Pérez-Is; Julio Collazos; Belén de la Fuente; Luis Morano; Maria Rivas-Carmenado; Manuel Rodriguez; Adolfo Romero-Favela; Galilea de Jesús Fonseca-González; Santiago Melón; Eulalia Valle-Garay; Víctor Asensi
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.379

Review 3.  Present and future management of viral hepatitis.

Authors:  Rocío González Grande; Inmaculada Santaella Leiva; Susana López Ortega; Miguel Jiménez Pérez
Journal:  World J Gastroenterol       Date:  2021-12-21       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.